U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07522801) titled 'A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH.' on April 04.
Brief Summary: To evaluate the benefit of a precision medicine based strategy (targeted therapeutic options (TTOs)) for patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) (in terms of composite remission).
Study Start Date: Sept. 01, 2026
Study Type: INTERVENTIONAL
Condition:
LAL
Intervention:
DRUG: Venetoclax + Tofacitinib
Cycle 1:
Venetoclax, 100 mg/d PO day1; 200 mg/d day2; 300 mg/d day3 and 400 mg/day thereafter (100 mg/day in case of ...